Medivolve Announces AGM Results and Closing of Shares for Debt Transaction

TORONTO, Nov. 22, 2021 /PRNewswire/ - Medivolve, Inc. ("Medivolve" or the "Company") (NEO: MEDV) (OTC: COPRF) (FRA: 4NC), reports, in accordance with the policies of the NEO Exchange, that the nominees listed in the Management Information Circular dated October 22, 2021 for the 2021 Annual and Special Meeting of Shareholders of the Company (the "Meeting") were elected as directors of the Company. 14.12% of all of the issued and outstanding shares of the Company were represented at the Meeting. 

Detailed results of the vote for the election of directors held at the Meeting on November 22, 2021, in Toronto, Ontario are set out below.

Election of Directors

The shareholders approved the election as directors of the persons listed below, based on the following vote.

Shareholders at the annual meeting also approved the appointment of the Company's auditors, McGovern Hurley LLP, the re-approval of the Corporation's rolling stock option plan and a consolidation of the Company's common shares on the basis of up to 15 to 1.

Medivolve's board of directors would like to express its gratitude to its shareholders for their continued support.

Shares for Debt

The Company also announces that it has closed its previously announced settlement of $441,000 of its outstanding cash indebtedness owed to a creditor by way of the issuance of 6,300,000 common shares of the Company (the "Common Shares") at an effective price per share of $0.07. In accordance with applicable securities laws, the Common Shares issued are subject to a four month and one day hold period.

About Medivolve, Inc.

Medivolve, Inc. (NEO: MEDV; OTC: COPRF; FRA:4NC) is a healthcare technology company that seeks to reinvent the U.S. healthcare system by leveraging a bespoke telehealth platform, a clinical diagnostic network, and a data driven A.I. framework to improve patient care.

The company was born out of the healthcare crisis; to rethink, relearn and ultimately, reimagine a better way for the healthcare system to operate. Our network of retail collection sites plays an essential role in recovery by giving all Americans access to fast, accurate, and inexpensive clinical services when and where they need them. These centers will also play a pivotal role in diagnostic testing, vaccinations, and other point-of-care services. We are building disruptive technologies to make it easier and faster to identify, treat, and prevent medical issues. In doing so, we are working to give patients a holistic and empowered view of their personal health.

Our long-term mission is to permanently fix systemic issues in the nation's fragmented, overly complex, and expensive healthcare system. Medivolve's next growth phase is about pivoting the model and putting the pieces together to build a profitable, SaaS-based health-tech company. We bring data-driven clinical diagnostics, physician recommendations, and prescription medications directly to people, all powered by a singular, streamlined technology network. A powerful, singular purpose unites our team: harnessing the transformative power of technology to create healthier lives.

Underpinned by a bespoke, AI-driven platform, we're developing a stealth system that constantly gets smarter, takes the guesswork out of diagnostics, and flags critical health issues immediately to deliver an unparalleled level of personalization for each patient. We are determined to push the boundaries of what's possible—not just for our business and our shareholders, but for physicians and patients and the future of healthcare. We strive to achieve a continuity of care never seen before, a game-changer for our business and patients in the communities we serve.

Cautionary Note Regarding Forward-looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the pursuit by Medivolve of disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and the merits or potential returns of any such pursuits. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including but not limited to: receipt of necessary approvals; general business, economic, competitive, political and social uncertainties; the continued spread of COVID-19; labour disputes and shortages; and other risks of the medical industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

SOURCE Medivolve Inc.

Related Links

www.medivolve.net

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED